The Secretary, acting through the Director of NIH, may make awards to an entity or entities described in paragraph (4) to build upon existing research efforts to collect biospecimens and clinical and demographic information of children, adolescents, and young adults with selected cancer subtypes (and their recurrences) for which current treatments are least effective, in order to achieve a better understanding of the causes of such cancer subtypes (and their recurrences), and the effects and outcomes of treatments for such cancers.
Amounts received under an award under paragraph (1) may be used to carry out the following:
No child, adolescent, or young adult with cancer shall be required under this subsection to contribute a specimen to a biorepository or share clinical or demographic data.
To be eligible to receive an award under paragraph (1) an entity shall submit an application to the Secretary at such a time, in such manner, and containing such information as the Secretary may reasonably require.
In evaluating applications submitted under subparagraph (A), the Secretary shall consider the existing infrastructure of the entity that would allow for the timely capture of biospecimens and related clinical and demographic information for children, adolescents, and young adults with cancer for whom current treatments are least effective.
The Secretary may not make an award under paragraph (1) to an entity unless the Secretary ensures that such entity-
The Secretary shall ensure biospecimens and associated clinical and demographic information are collected with informed consent, as described in subparagraph (A)(i).
The Secretary shall develop and disseminate appropriate guidelines for the development and maintenance of the biorepositories supported under this subsection, including appropriate oversight, to facilitate further research on select cancer subtypes (and their recurrences) in children, adolescents, and young adults with such cancers (and their recurrences).
To encourage the greatest possible efficiency and effectiveness of federally supported efforts with respect to the activities described in this subsection, the Secretary shall ensure the appropriate coordination of programs supported under this section with existing federally supported cancer registry programs and the activities under section 280e-3a of this title, as appropriate.
Funds provided under this subsection shall be used to supplement, and not supplant, Federal and non-Federal funds available for carrying out the activities described in this subsection.
Not later than 4 years after January 5, 2023, the Secretary shall submit to Congress a report on-
Not later than 2 years after January 5, 2023, the Director of NIH shall-
For purposes of this subsection:
The term "award" includes a grant, contract, or cooperative agreement determined by the Secretary.
The term "biospecimen" includes-
The term "clinical and demographic information" includes-
The Director of NIH, in coordination with ongoing research activities, may continue to conduct or support pediatric cancer survivorship research including in any of the following areas:
In conducting or supporting research under paragraph (1)(A)(i) on pediatric cancer survivors within minority or other medically underserved populations, the Director of NIH shall ensure that such research addresses both the physical and the psychological needs of such survivors, as appropriate.
Nothing in this section shall be construed as being inconsistent with the goals and purposes of the Minority Health and Health Disparities Research and Education Act of 2000.
For purposes of carrying out this section and section 280e-3a of this title, there are authorized to be appropriated $30,000,000 for each of fiscal years 2024 through 2028. Funds appropriated under this subsection shall remain available until expended.
42 U.S.C. § 285a-11
EDITORIAL NOTES
REFERENCES IN TEXTThe Minority Health and Health Disparities Research and Education Act of 2000, referred to in subsec. (c), is Pub. L. 106-525, 114 Stat. 2495. For complete classification of this Act to the Code, see Short Title of 2000 Amendments note set out under section 201 of this title and Tables.
AMENDMENTS2023-Subsec. (a)(2)(A). Pub. L. 117-350, §2(a)(1)(A), inserted ",such as collected samples of both solid tumor cancer and paired samples" after "National Cancer Institute". Subsec. (a)(9). Pub. L. 117-350, §2(a)(1)(B), substituted "January 5, 2023" for "June 5, 2018" in introductory provisions. Subsec. (a)(10), (11). Pub. L. 117-350, §2(a)(1)(C), (D), added par. (10) and redesignated former par. (10) as (11).Subsec. (d). Pub. L. 117-350, §2(a)(2), substituted "2024 through 2028" for "2019 through 2023". 2018- Pub. L. 115-180, §101(1), substituted "research, awareness, and survivorship" for "research and awareness" in section catchline.Subsec. (a). Pub. L. 115-180, §101(2), added subsec. (a) and struck out former subsec. (a). Prior to amendment, text read as follows:"(1) PROGRAMS OF RESEARCH EXCELLENCE IN PEDIATRIC CANCER.-The Secretary, in collaboration with the Director of NIH and other Federal agencies with interest in prevention and treatment of pediatric cancer, shall continue to enhance, expand, and intensify pediatric cancer research and other activities related to pediatric cancer, including therapeutically applicable research to generate effective treatments, pediatric preclinical testing, and pediatric clinical trials through National Cancer Institute-supported pediatric cancer clinical trial groups and their member institutions. In enhancing, expanding, and intensifying such research and other activities, the Secretary is encouraged to take into consideration the application of such research and other activities for minority, health disparity, and medically underserved communities. For purposes of this section, the term 'pediatric cancer research' means research on the causes, prevention, diagnosis, recognition, treatment, and long-term effects of pediatric cancer."(2) PEER REVIEW REQUIREMENTS.-All grants awarded under this subsection shall be awarded in accordance with section 289a of this title."Subsec. (b). Pub. L. 115-180, §202, added subsec. (b) and struck out former subsec. (b) which related to public awareness of pediatric cancers and available treatments and research. Subsec. (c). Pub. L. 115-180, §101(3), struck out "(42 U.S.C. 202 note)" before period at end.Subsec. (d). Pub. L. 115-180, §102(b), substituted "2019 through 2023" for "2009 through 2013" and struck out "Such authorization of appropriations is in addition to the authorization of appropriations established in section 282a of this title with respect to such purpose." before "Funds appropriated".
STATUTORY NOTES AND RELATED SUBSIDIARIES
REPORTING ON CHILDHOOD CANCER RESEARCH PROJECTS Pub. L. 115-180, title I, §121, June 5, 2018, 132 Stat. 1387, provided that: "The Director of the National Institutes of Health shall ensure that childhood cancer research projects conducted or supported by the National Institutes of Health are included in appropriate reports to Congress, which may include the Pediatric Research Initiative report."
- Secretary
- The term "Secretary" means the Secretary of Housing and Urban Development.1See References in Text note below.